Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$313.65
+0.9%
$300.37
$218.31
$385.22
$34.41B0.5254,077 shs138,131 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$12.43
-5.4%
$13.67
$12.19
$16.17
$10.36B0.272.22 million shs2.83 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$141.73
-1.7%
$115.02
$34.00
$155.70
$30.18B1.413.45 million shs307,708 shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$35.31
-1.5%
$31.36
$14.99
$37.35
$40.60B0.868.18 million shs1.73 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-0.44%+5.75%+0.35%-12.08%+33.95%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.79%-4.23%-1.35%-6.37%-2.05%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+1.65%+3.35%+49.49%+50.08%+255.22%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.55%+2.60%+16.62%+4.51%+111.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$313.65
+0.9%
$300.37
$218.31
$385.22
$34.41B0.5254,077 shs138,131 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$12.43
-5.4%
$13.67
$12.19
$16.17
$10.36B0.272.22 million shs2.83 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$141.73
-1.7%
$115.02
$34.00
$155.70
$30.18B1.413.45 million shs307,708 shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$35.31
-1.5%
$31.36
$14.99
$37.35
$40.60B0.868.18 million shs1.73 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-0.44%+5.75%+0.35%-12.08%+33.95%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.79%-4.23%-1.35%-6.37%-2.05%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+1.65%+3.35%+49.49%+50.08%+255.22%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.55%+2.60%+16.62%+4.51%+111.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.79
Moderate Buy$391.0024.49% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$16.9037.34% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.10
Buy$103.88-27.02% Downside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.80
Moderate Buy$41.7818.27% Upside

Current Analyst Ratings Breakdown

Latest RDY, TEVA, ONC, and RVMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingOverweight$395.00
5/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetBuy$410.00 ➝ $420.00
5/7/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetBuy$205.00
5/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOverweight$405.00 ➝ $409.00
5/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$423.00 ➝ $425.00
5/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingBuy$411.00 ➝ $413.00
5/7/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetOutperform$165.00
5/7/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetOutperform$165.00
5/7/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetOverweight$172.00
5/6/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Boost Price TargetOverweight$38.00 ➝ $40.00
5/4/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Initiated CoverageOverweight$400.00
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.74B6.00$3.93 per share79.86$39.77 per share7.90
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B2.69$0.96 per share12.81$4.73 per share2.60
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M2,612.98N/AN/A$8.44 per share16.86
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.26B2.35$3.69 per share9.58$6.88 per share5.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4770.3530.58N/A8.94%12.06%6.69%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.7716.0021.2220.5516.41%15.89%10.73%5/12/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%N/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.41B$1.3326.5611.623.459.01%43.53%8.19%7/29/2026 (Estimated)

Latest RDY, TEVA, ONC, and RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09N/AN/AN/A$886.58 millionN/A
5/6/2026Q1 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A
4/29/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion
4/1/2026Q1 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/A$0.25N/A$1.95N/A$1.51 billion
3/31/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/A$0.53N/A$0.31N/A$3.98 billion
2/26/2026Q4 2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$1.60$0.58-$1.02$0.58$1.45 billion$1.50 billion
2/25/2026Q4 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.56-$1.86-$0.30-$1.86$3.89 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.57%+9.86%9.09%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.88
1.38
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.19
6.80
6.80
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1.70
1.01
0.78
CompanyEmployeesShares OutstandingFree FloatOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.65 million817.96 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250212.60 million195.16 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
33,9501.15 billion1.14 billionOptionable

Recent News About These Companies

Teva's CNS Portfolio Is Growing, But Valuation Is Stretched

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$313.65 +2.90 (+0.93%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$12.42 -0.72 (-5.44%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$141.73 -2.42 (-1.68%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$35.31 -0.53 (-1.48%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.